Literature DB >> 23871779

Allogeneic hematopoietic cell transplantation in septuagenarians.

Michael R Grunwald1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23871779      PMCID： PMC4476526          DOI： 10.1016/j.bbmt.2013.07.012

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  22 in total

1.  Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation.

Authors:  Andrew S Artz; Daniel A Pollyea; Masha Kocherginsky; Wendy Stock; Elizabeth Rich; Olatoyosi Odenike; Todd Zimmerman; Sonali Smith; Lucy Godley; Michael Thirman; Christopher Daugherty; Martine Extermann; Richard Larson; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2006-09       Impact factor: 5.742

2.  Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.

Authors:  R M Stone; D T Berg; S L George; R K Dodge; P A Paciucci; P P Schulman; E J Lee; J O Moore; B L Powell; M R Baer; C D Bloomfield; C A Schiffer
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

3.  Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Authors:  Andrew M Brunner; Haesook T Kim; Erin Coughlin; Edwin P Alyea; Philippe Armand; Karen K Ballen; Corey Cutler; Bimalangshu R Dey; Brett Glotzbecker; John Koreth; Steven L McAfee; Thomas R Spitzer; Robert J Soiffer; Joseph H Antin; Vincent T Ho; Yi-Bin Chen
Journal:  Biol Blood Marrow Transplant       Date:  2013-06-18       Impact factor: 5.742

4.  Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

Authors:  Elihu Estey; Marcos de Lima; Raoul Tibes; Sherry Pierce; Hagop Kantarjian; Richard Champlin; Sergio Giralt
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

5.  Age and acute myeloid leukemia.

Authors:  Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

6.  Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.

Authors:  Mohamed L Sorror; Michael B Maris; Barry Storer; Brenda M Sandmaier; Razvan Diaconescu; Christopher Flowers; David G Maloney; Rainer Storb
Journal:  Blood       Date:  2004-04-27       Impact factor: 22.113

7.  Bone marrow transplantation in patients aged 45 years and older.

Authors:  H G Klingemann; R Storb; A Fefer; H J Deeg; F R Appelbaum; C D Buckner; M A Cheever; P D Greenberg; P S Stewart; K M Sullivan
Journal:  Blood       Date:  1986-03       Impact factor: 22.113

8.  Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.

Authors:  John Koreth; Julie Aldridge; Haesook T Kim; Edwin P Alyea; Corey Cutler; Philippe Armand; Jerome Ritz; Joseph H Antin; Robert J Soiffer; Vincent T Ho
Journal:  Biol Blood Marrow Transplant       Date:  2010-01-13       Impact factor: 5.742

9.  Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.

Authors:  Steven M Devine; Kouros Owzar; William Blum; Flora Mulkey; Richard M Stone; Jack W Hsu; Richard E Champlin; Yi-Bin Chen; Ravi Vij; James Slack; Robert J Soiffer; Richard A Larson; Thomas C Shea; Vera Hars; Alexander B Sibley; Sergio Giralt; Shelly Carter; Mary M Horowitz; Charles Linker; Edwin P Alyea
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

10.  Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Authors:  Gunnar Juliusson; Petar Antunovic; Asa Derolf; Sören Lehmann; Lars Möllgård; Dick Stockelberg; Ulf Tidefelt; Anders Wahlin; Martin Höglund
Journal:  Blood       Date:  2008-11-13       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.